Home / Health / New mRNA Vaccine Fights Melanoma Recurrence
New mRNA Vaccine Fights Melanoma Recurrence
1 Jun
Summary
- An mRNA vaccine combined with Keytruda significantly reduced melanoma recurrence.
- Five-year follow-up showed 68.8% of patients remained cancer-free with combination therapy.
- The personalized vaccine trains T cells to target specific neoantigens from tumors.
A novel approach combining an mRNA vaccine with the immunotherapy drug Keytruda has shown significant promise in preventing melanoma recurrence.
In a trial involving 157 patients in Australia and the U.S., those who received the combination therapy had a 49% lower risk of recurrence compared to those treated with Keytruda alone. After five years, 68.8% of patients on the combination therapy remained cancer-free, versus 49.1% for Keytruda alone.
The personalized mRNA vaccine is created by sequencing a patient's tumor to identify unique molecular fingerprints, or neoantigens. This custom vaccine then trains T cells to recognize and target these specific cancer markers, effectively providing the immune system with a blueprint to attack the disease.
This innovative treatment strategy also demonstrated improved survival rates, with 92% of patients on the combination therapy alive at the five-year mark, compared to 71% on Keytruda alone. Researchers are exploring its use for other cancers, such as lung cancer, with a larger Phase 3 trial currently underway.
